Clinical Trials

April 24, 2025

Learn how gemtuzumab ozogamicin improves survival in children with acute myeloid leukemia and discuss options with your healthcare team.

April 16, 2025

Understanding how ROR1-targeted therapies work—and whether they apply to your specific blood cancer type—can help you make more informed treatment decisions.

February 16, 2025

Learn how uproleselan may improve treatment outcomes for relapsed or refractory acute myeloid leukemia patients in this latest clinical study.

October 29, 2024

Explore iadademstat for AML treatment in Oryzon Genomics' latest clinical trials with promising results.

October 22, 2024

What is RVU120, a new medicine in clinical trials, and how may it help reduce signs/symptoms of AML, MDS, and myelofibrosis?

October 09, 2024

Explore the AMpLify trial testing CRISPR-edited CAR-T therapy CB-012 for relapsed/refractory AML, now recruiting patients for Phase 1.

September 15, 2024

Promising new off-the-shelf CAR NK cell therapy, SENTI-202, offers hope for relapsed/refractory AML & MDS. Learn about eligibility and trial locations.

July 12, 2024

AML specialist Harry Erba, MD, PhD, shared insight about a new treatment decision-making model for AML and MDS patients called myeloMATCH.

May 16, 2024

Here we take a look at the drug, gemtuzumab ozogamicin, and its efficacy on relapsed or refractory AML.

March 06, 2024

Bisantrene has shown significant advancement in the treatment of R/R AML.